首页 > 最新文献

Annals of Nuclear Medicine最新文献

英文 中文
Impact of recent COVID-19 infection on perfusion and functional parameters derived from gated myocardial perfusion imaging in patients undergoing evaluation for coronary artery disease: correspondence 近期感染 COVID-19 对接受冠状动脉疾病评估的患者门控心肌灌注成像得出的灌注和功能参数的影响:通信。
IF 2.5 4区 医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2024-07-15 DOI: 10.1007/s12149-024-01961-1
Hinpetch Daungsupawong, Viroj Wiwanitkit
{"title":"Impact of recent COVID-19 infection on perfusion and functional parameters derived from gated myocardial perfusion imaging in patients undergoing evaluation for coronary artery disease: correspondence","authors":"Hinpetch Daungsupawong, Viroj Wiwanitkit","doi":"10.1007/s12149-024-01961-1","DOIUrl":"10.1007/s12149-024-01961-1","url":null,"abstract":"","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"38 10","pages":"852 - 852"},"PeriodicalIF":2.5,"publicationDate":"2024-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141615797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Physiological biodistribution on Ga68-PSMA PET/CT and the factors effecting biodistribution Ga68-PSMA PET/CT 的生理生物分布以及影响生物分布的因素。
IF 2.5 4区 医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2024-07-09 DOI: 10.1007/s12149-024-01957-x
Ayça Arçay Öztürk, Metin Erkılıç, Gonca Gül Bural, Funda Aydın, Adil Boz

Aim

The study aims to determine the physiological and pathophysiological distribution of the radiopharmaceutical (Ga68-PSMA-617) and investigate whether there are differences in distribution according to the laboratory, histopathological and clinical findings that can affect image evaluation. Also, we aimed to determine cut-off values to distinguish physiological and pathological uptake in prostate, bone, and lymph nodes.

Materials and Methods

229 prostate cancer patients who underwent Ga68-PSMA PET/CT at our department were retrospectively analyzed. The patients were grouped according to PET/CT results, Gleason scores, PSA values, received treatments, metastatic status and other laboratory values. The SUV values of the organs, tissues, and pathological lesions of the patients in these subgroups were compared among themselves.

Results

No significant difference was detected in the physiological uptake of lymph nodes and bone between the groups. In the group with patients that received androgen deprivation therapy (ADT), the bone metastasis SUV values were found to be higher and the SUV values of the submandibular gland and renal cortex were found to be lower (Mann–Whitney U, p = 0.043; 0.004; 0.01, respectively). In the group with patients who received radiotherapy, the normal prostate tissue SUV values were determined to be higher (Mann–Whitney U, p = 0.009). The SUV values of the submandibular gland, muscle, liver, and blood pool were found to be lower in the group of patients with high serum LDH values. The cut-off SUVmax value was determined to be 6.945 (sensitivity 89.6%, specificity 98.1%) for primary prostate lesion; 4.72 for lymph node metastasis; 4.25 for bone metastasis. The serum PSA cut-off value to distinguish the negative/positive groups was found to be 1,505 (sensitivity 79.7%, specificity 77.3%).

Conclusion

In conclusion, PSMA-617 demonstrates a similar biodistribution with other PSMA ligands. The physiological uptake of lymph nodes and bone which are mostly metastasized in prostate cancer, are not affected by the factors we examined. It should be kept in mind that the normal prostate tissue uptake may increase in patients receiving radiotherapy, and the physiological/pathological uptake of the organs may differ due to the changes in PSMA expression in patients receiving ADT, tumor burden, and kidney function may affect the biodistribution.

目的:本研究旨在确定放射性药物(Ga68-PSMA-617)的生理学和病理生理学分布,并研究根据实验室、组织病理学和临床发现的分布差异是否会影响图像评估。此外,我们还旨在确定临界值,以区分前列腺、骨和淋巴结的生理性和病理性摄取。材料与方法:我们对在我科接受Ga68-PSMA PET/CT检查的229名前列腺癌患者进行了回顾性分析。根据 PET/CT 结果、Gleason 评分、PSA 值、接受的治疗、转移状态和其他实验室值对患者进行分组。对这些亚组患者的器官、组织和病理病变的 SUV 值进行了比较:结果:各组淋巴结和骨骼的生理学摄取量无明显差异。在接受雄激素剥夺疗法(ADT)的患者组中,骨转移SUV值较高,而颌下腺和肾皮质的SUV值较低(Mann-Whitney U,P分别为0.043;0.004;0.01)。在接受放疗的患者组中,正常前列腺组织的 SUV 值被确定为更高(Mann-Whitney U,p = 0.009)。在血清 LDH 值较高的患者组中,颌下腺、肌肉、肝脏和血池的 SUV 值较低。原发性前列腺病变的 SUVmax 临界值为 6.945(敏感性 89.6%,特异性 98.1%);淋巴结转移的 SUVmax 临界值为 4.72;骨转移的 SUVmax 临界值为 4.25。区分阴性/阳性组的血清 PSA 临界值为 1,505(敏感性 79.7%,特异性 77.3%):总之,PSMA-617与其他PSMA配体具有相似的生物分布。淋巴结和骨的生理性摄取是前列腺癌转移的主要部位,不受我们所研究因素的影响。需要注意的是,接受放疗的患者的正常前列腺组织摄取量可能会增加,而由于接受 ADT 的患者 PSMA 表达的变化、肿瘤负荷和肾功能可能会影响生物分布,器官的生理学/病理学摄取量可能会有所不同。
{"title":"Physiological biodistribution on Ga68-PSMA PET/CT and the factors effecting biodistribution","authors":"Ayça Arçay Öztürk,&nbsp;Metin Erkılıç,&nbsp;Gonca Gül Bural,&nbsp;Funda Aydın,&nbsp;Adil Boz","doi":"10.1007/s12149-024-01957-x","DOIUrl":"10.1007/s12149-024-01957-x","url":null,"abstract":"<div><h3>Aim</h3><p>The study aims to determine the physiological and pathophysiological distribution of the radiopharmaceutical (Ga<sup>68</sup>-PSMA-617) and investigate whether there are differences in distribution according to the laboratory, histopathological and clinical findings that can affect image evaluation. Also, we aimed to determine cut-off values to distinguish physiological and pathological uptake in prostate, bone, and lymph nodes.</p><h3>Materials and Methods</h3><p>229 prostate cancer patients who underwent Ga<sup>68</sup>-PSMA PET/CT at our department were retrospectively analyzed. The patients were grouped according to PET/CT results, Gleason scores, PSA values, received treatments, metastatic status and other laboratory values. The SUV values of the organs, tissues, and pathological lesions of the patients in these subgroups were compared among themselves.</p><h3>Results</h3><p>No significant difference was detected in the physiological uptake of lymph nodes and bone between the groups. In the group with patients that received androgen deprivation therapy (ADT), the bone metastasis SUV values were found to be higher and the SUV values of the submandibular gland and renal cortex were found to be lower (Mann–Whitney <i>U</i>, <i>p</i> = 0.043; 0.004; 0.01, respectively). In the group with patients who received radiotherapy, the normal prostate tissue SUV values were determined to be higher (Mann–Whitney <i>U</i>, <i>p</i> = 0.009). The SUV values of the submandibular gland, muscle, liver, and blood pool were found to be lower in the group of patients with high serum LDH values. The cut-off SUVmax value was determined to be 6.945 (sensitivity 89.6%, specificity 98.1%) for primary prostate lesion; 4.72 for lymph node metastasis; 4.25 for bone metastasis. The serum PSA cut-off value to distinguish the negative/positive groups was found to be 1,505 (sensitivity 79.7%, specificity 77.3%).</p><h3>Conclusion</h3><p>In conclusion, PSMA-617 demonstrates a similar biodistribution with other PSMA ligands. The physiological uptake of lymph nodes and bone which are mostly metastasized in prostate cancer, are not affected by the factors we examined. It should be kept in mind that the normal prostate tissue uptake may increase in patients receiving radiotherapy, and the physiological/pathological uptake of the organs may differ due to the changes in PSMA expression in patients receiving ADT, tumor burden, and kidney function may affect the biodistribution.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"38 11","pages":"894 - 903"},"PeriodicalIF":2.5,"publicationDate":"2024-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s12149-024-01957-x.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141557894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Novel technetium-99m-labeled bivalent PSMA-targeting probe based on hydroxamamide chelate for diagnosis of prostate cancer 基于羟酰胺螯合物的新型锝-99m 标记二价 PSMA 靶向探针用于诊断前列腺癌。
IF 2.5 4区 医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2024-07-08 DOI: 10.1007/s12149-024-01959-9
Yoichi Shimizu, Masato Ando, Hiroyuki Watanabe, Masahiro Ono

Objective

Prostate-specific membrane antigen (PSMA) is a well-known biomarker of prostate cancer. Previously, our group reported that the succinimidyl–cystatin–urea–glutamate (SCUE) moiety has a high affinity for PSMA. In this study, we developed the novel technetium-99m-labeled PSMA-targeting probe “[99mTc]Tc-(Ham-SCUE)2” based on a hydroxamamide chelate with a bivalent SCUE and evaluated its potential as a SPECT imaging probe for the diagnosis of PSMA-expressing prostate cancer.

Methods

Ham-SCUE was synthesized by a one-step reaction with Ham-Mal and cysteine-urea-glutamine. Then, Ham-SCUE was reacted with [99mTc]NaTcO4 for 10 min at room temperature to obtain [99mTc]Tc-(Ham-SCUE)2. [99mTc]Tc-(Ham-SCUE)2 was added to LNCaP (high PSMA expression) cells or PC3 (low PSMA expression) cells, and their radioactivity was measured 60 min after administration. The blocking study was performed by co-incubation of LNCaP cells with various concentrations of 2-PMPA (a PSMA inhibitor) for 15 min before adding [99mTc]Tc-(Ham-SCUE)2. The biodistribution of [99mTc]Tc-(Ham-SCUE)2 in LNCaP/PC3 dual xenografted C.B.-17/Icr scid/scid Jcl mice was evaluated for 120 min after intravenous injection. The blocking study was performed by pretreatment of mice with 2-PMPA (10 mg/kg weight).

Results

[99mTc]Tc-(Ham-SCUE)2 was acquired at radiochemical yields of 56% with a radiochemical purity of over 95%. The cellular uptake level of [99mTc]Tc-(Ham-SCUE)2 by LNCaP cells was significantly higher than that by PC3 cells (LNCaP: 11.12 ± 0.71 vs. PC3: 1.40 ± 0.13%uptake/mg protein, p < 0.01), and the uptake was significantly suppressed by pretreatment with 2-PMPA (2.56 ± 0.37%uptake/mg protein, p < 0.05). IC50 of 2-PMPA was 245 ± 47 nM. In the in vivo study, the radioactivity of LNCaP tumor tissue was significantly higher than that of PC3 tumor tissue at 120 min after the administration of [99mTc]Tc-(Ham-SCUE)2 (LNCaP: 9.97 ± 2.79, PC3: 1.16 ± 0.23%ID/g, p < 0.01), and was suppressed by pretreatment with 2-PMPA (2.50 ± 0.45%ID/g, p < 0.01).

Conclusion

[99mTc]Tc-(Ham-SCUE)2 has the potential to be a SPECT imaging agent for diagnosing high PSMA-expressing prostate cancer.

目的:前列腺特异性膜抗原(PSMA前列腺特异性膜抗原(PSMA)是众所周知的前列腺癌生物标志物。此前,我们的研究小组曾报道,琥珀酰亚胺基-胱抑素-脲-谷氨酸(SCUE)分子与 PSMA 有很高的亲和力。本研究中,我们开发了新型锝-99m 标记 PSMA 靶向探针"[99mTc]Tc-(Ham-SCUE)2",该探针基于含二价 SCUE 的羟酰胺螯合物,并评估了其作为 SPECT 成像探针诊断表达 PSMA 的前列腺癌的潜力。将[99mTc]Tc-(Ham-SCUE)2加入LNCaP(PSMA高表达)细胞或PC3(PSMA低表达)细胞,60分钟后测量其放射性。阻断研究是在加入[99mTc]Tc-(Ham-SCUE)2 之前,先将 LNCaP 细胞与不同浓度的 2-PMPA(一种 PSMA 抑制剂)共孵育 15 分钟。静脉注射[99mTc]Tc-(Ham-SCUE)2 120 分钟后,评估了[99mTc]Tc-(Ham-SCUE)2 在 LNCaP/PC3 双异种移植 C.B.-17/Icr scid/scid Jcl 小鼠体内的生物分布情况。阻断研究是通过对小鼠进行 2-PMPA(10 毫克/千克体重)预处理进行的:结果:[99m锝]Tc-(Ham-SCUE)2的放射化学收率为56%,放射化学纯度超过95%。LNCaP细胞对[99mTc]Tc-(Ham-SCUE)2的摄取水平明显高于PC3细胞(LNCaP:11.12 ± 0.71 vs. PC3:1.40 ± 0.13%uptake/mg protein,2-PMPA的p 50为245 ± 47 nM)。在体内研究中,给予[99mTc]Tc-(Ham-SCUE)2 120 分钟后,LNCaP 肿瘤组织的放射性明显高于 PC3 肿瘤组织(LNCaP:9.97 ± 2.79,PC3:1.16 ± 0.23%ID/g,p 结论:[99mTc]Tc-(Ham-SCUE)2 对 PC3 肿瘤组织的放射性没有影响:[99mTc]Tc-(Ham-SCUE)2 有潜力成为诊断高 PSMA 表达前列腺癌的 SPECT 成像剂。
{"title":"Novel technetium-99m-labeled bivalent PSMA-targeting probe based on hydroxamamide chelate for diagnosis of prostate cancer","authors":"Yoichi Shimizu,&nbsp;Masato Ando,&nbsp;Hiroyuki Watanabe,&nbsp;Masahiro Ono","doi":"10.1007/s12149-024-01959-9","DOIUrl":"10.1007/s12149-024-01959-9","url":null,"abstract":"<div><h3>Objective</h3><p>Prostate-specific membrane antigen (PSMA) is a well-known biomarker of prostate cancer. Previously, our group reported that the succinimidyl–cystatin–urea–glutamate (SCUE) moiety has a high affinity for PSMA. In this study, we developed the novel technetium-99m-labeled PSMA-targeting probe “[<sup>99m</sup>Tc]Tc-(Ham-SCUE)<sub>2</sub>” based on a hydroxamamide chelate with a bivalent SCUE and evaluated its potential as a SPECT imaging probe for the diagnosis of PSMA-expressing prostate cancer.</p><h3>Methods</h3><p>Ham-SCUE was synthesized by a one-step reaction with Ham-Mal and cysteine-urea-glutamine. Then, Ham-SCUE was reacted with [<sup>99m</sup>Tc]NaTcO<sub>4</sub> for 10 min at room temperature to obtain [<sup>99m</sup>Tc]Tc-(Ham-SCUE)<sub>2</sub>. [<sup>99m</sup>Tc]Tc-(Ham-SCUE)<sub>2</sub> was added to LNCaP (high PSMA expression) cells or PC3 (low PSMA expression) cells, and their radioactivity was measured 60 min after administration. The blocking study was performed by co-incubation of LNCaP cells with various concentrations of 2-PMPA (a PSMA inhibitor) for 15 min before adding [<sup>99m</sup>Tc]Tc-(Ham-SCUE)<sub>2</sub>. The biodistribution of [<sup>99m</sup>Tc]Tc-(Ham-SCUE)<sub>2</sub> in LNCaP/PC3 dual xenografted C.B.-17/Icr scid/scid Jcl mice was evaluated for 120 min after intravenous injection. The blocking study was performed by pretreatment of mice with 2-PMPA (10 mg/kg weight).</p><h3>Results</h3><p>[<sup>99m</sup>Tc]Tc-(Ham-SCUE)<sub>2</sub> was acquired at radiochemical yields of 56% with a radiochemical purity of over 95%. The cellular uptake level of [<sup>99m</sup>Tc]Tc-(Ham-SCUE)<sub>2</sub> by LNCaP cells was significantly higher than that by PC3 cells (LNCaP: 11.12 ± 0.71 vs. PC3: 1.40 ± 0.13%uptake/mg protein, <i>p</i> &lt; 0.01), and the uptake was significantly suppressed by pretreatment with 2-PMPA (2.56 ± 0.37%uptake/mg protein, <i>p</i> &lt; 0.05). IC<sub>50</sub> of 2-PMPA was 245 ± 47 nM. In the in vivo study, the radioactivity of LNCaP tumor tissue was significantly higher than that of PC3 tumor tissue at 120 min after the administration of [<sup>99m</sup>Tc]Tc-(Ham-SCUE)<sub>2</sub> (LNCaP: 9.97 ± 2.79, PC3: 1.16 ± 0.23%ID/g, <i>p</i> &lt; 0.01), and was suppressed by pretreatment with 2-PMPA (2.50 ± 0.45%ID/g, <i>p</i> &lt; 0.01).</p><h3>Conclusion</h3><p>[<sup>99m</sup>Tc]Tc-(Ham-SCUE)<sub>2</sub> has the potential to be a SPECT imaging agent for diagnosing high PSMA-expressing prostate cancer.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"38 10","pages":"847 - 851"},"PeriodicalIF":2.5,"publicationDate":"2024-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141554095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New objective simple evaluation methods of amyloid PET/CT using whole-brain histogram and Top20%-Map 利用全脑直方图和 Top20% 地图对淀粉样蛋白 PET/CT 进行客观简单评估的新方法。
IF 2.5 4区 医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2024-06-22 DOI: 10.1007/s12149-024-01956-y
Chio Okuyama, Tatsuya Higashi, Koichi Ishizu, Naoya Oishi, Kuninori Kusano, Miki Ito, Shinya Kagawa, Tomoko Okina, Norio Suzuki, Hiroshi Hasegawa, Yasuhiro Nagahama, Hiroyuki Watanabe, Masahiro Ono, Hiroshi Yamauchi

Objective

This study aims to assess the utility of newly developed objective methods for the evaluation of intracranial abnormal amyloid deposition using PET/CT histogram without use of cortical ROI analyses.

Methods

Twenty-five healthy volunteers (HV) and 38 patients with diagnosed or suspected dementia who had undergone 18F-FPYBF-2 PET/CT were retrospectively included in this study. Out of them, 11C-PiB PET/CT had been also performed in 13 subjects. In addition to the conventional methods, namely visual judgment and quantitative analyses using composed standardized uptake value ratio (comSUVR), the PET images were also evaluated by the following new parameters: the skewness and the mode-to-mean ratio (MMR) obtained from the histogram of the brain parenchyma; Top20%-map highlights the areas with high tracer accumulation occupying 20% volume of the total brain parenchymal on the individual’s CT images. We evaluated the utility of the new methods using histogram compared with the visual assessment and comSUVR. The results of these new methods between 18F-FPYBF-2 and 11C-PiB were also compared in 13 subjects.

Results

In visual analysis, 32, 9, and 22 subjects showed negative, border, and positive results, and composed SUVR in each group were 1.11 ± 0.06, 1.20 ± 0.13, and 1.48 ± 0.18 (p < 0.0001), respectively. Visually positive subjects showed significantly low skewness and high MMR (p < 0.0001), and the Top20%-Map showed the presence or absence of abnormal deposits clearly. In comparison between the two tracers, visual evaluation was all consistent, and the ComSUVR, the skewness, the MMR showed significant good correlation. The Top20%-Maps showed similar pattern.

Conclusions

Our new methods using the histogram of the brain parenchymal accumulation are simple and suitable for clinical practice of amyloid PET, and Top20%-Map on the individual’s brain CT can be of great help for the visual assessment.

研究目的本研究旨在评估新开发的客观方法在不使用皮层 ROI 分析的情况下使用 PET/CT 直方图评估颅内异常淀粉样蛋白沉积的实用性:本研究回顾性地纳入了25名健康志愿者(HV)和38名接受过18F-FPYBF-2 PET/CT检查的确诊或疑似痴呆患者。其中,13 名受试者还接受了 11C-PiB PET/CT 检查。除了传统的方法,即肉眼判断和使用组成标准化摄取值比(comSUVR)进行定量分析外,PET 图像还通过以下新参数进行了评估:从脑实质直方图中获得的偏度和模均比(MMR);Top20%-map 可突出显示个人 CT 图像中占总脑实质体积 20% 的高示踪剂累积区域。与目测评估和 comSUVR 相比,我们评估了使用直方图的新方法的实用性。我们还在 13 名受试者中比较了 18F-FPYBF-2 和 11C-PiB 这两种新方法的结果:结果:在目测分析中,32、9 和 22 名受试者的结果分别为阴性、边界和阳性,每组的 SUVR 分别为 1.11 ± 0.06、1.20 ± 0.13 和 1.48 ± 0.18(p 结论:我们使用直方图和 comSUVR 的新方法对 18F-FPYBF-2 和 11C-PiB 的结果进行了比较:我们利用脑实质堆积直方图的新方法简单易行,适合淀粉样蛋白 PET 的临床实践,而个人脑 CT 上的 Top20%-Map 对直观评估有很大帮助。
{"title":"New objective simple evaluation methods of amyloid PET/CT using whole-brain histogram and Top20%-Map","authors":"Chio Okuyama,&nbsp;Tatsuya Higashi,&nbsp;Koichi Ishizu,&nbsp;Naoya Oishi,&nbsp;Kuninori Kusano,&nbsp;Miki Ito,&nbsp;Shinya Kagawa,&nbsp;Tomoko Okina,&nbsp;Norio Suzuki,&nbsp;Hiroshi Hasegawa,&nbsp;Yasuhiro Nagahama,&nbsp;Hiroyuki Watanabe,&nbsp;Masahiro Ono,&nbsp;Hiroshi Yamauchi","doi":"10.1007/s12149-024-01956-y","DOIUrl":"10.1007/s12149-024-01956-y","url":null,"abstract":"<div><h3>Objective</h3><p>This study aims to assess the utility of newly developed objective methods for the evaluation of intracranial abnormal amyloid deposition using PET/CT histogram without use of cortical ROI analyses.</p><h3>Methods</h3><p>Twenty-five healthy volunteers (HV) and 38 patients with diagnosed or suspected dementia who had undergone <sup>18</sup>F-FPYBF-2 PET/CT were retrospectively included in this study. Out of them, <sup>11</sup>C-PiB PET/CT had been also performed in 13 subjects. In addition to the conventional methods, namely visual judgment and quantitative analyses using composed standardized uptake value ratio (comSUVR), the PET images were also evaluated by the following new parameters: the skewness and the mode-to-mean ratio (MMR) obtained from the histogram of the brain parenchyma; Top20%-map highlights the areas with high tracer accumulation occupying 20% volume of the total brain parenchymal on the individual’s CT images. We evaluated the utility of the new methods using histogram compared with the visual assessment and comSUVR. The results of these new methods between <sup>18</sup>F-FPYBF-2 and <sup>11</sup>C-PiB were also compared in 13 subjects.</p><h3>Results</h3><p>In visual analysis, 32, 9, and 22 subjects showed negative, border, and positive results, and composed SUVR in each group were 1.11 ± 0.06, 1.20 ± 0.13, and 1.48 ± 0.18 (<i>p</i> &lt; 0.0001), respectively. Visually positive subjects showed significantly low skewness and high MMR (<i>p</i> &lt; 0.0001), and the Top20%-Map showed the presence or absence of abnormal deposits clearly. In comparison between the two tracers, visual evaluation was all consistent, and the ComSUVR, the skewness, the MMR showed significant good correlation. The Top20%-Maps showed similar pattern.</p><h3>Conclusions</h3><p>Our new methods using the histogram of the brain parenchymal accumulation are simple and suitable for clinical practice of amyloid PET, and Top20%-Map on the individual’s brain CT can be of great help for the visual assessment.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"38 9","pages":"763 - 773"},"PeriodicalIF":2.5,"publicationDate":"2024-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11339116/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141440025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Differential centiloid scale normalization techniques: comparison between hybrid PET/MRI and independently acquired MRI 不同中心鳞片归一化技术:混合 PET/MRI 与独立获取的 MRI 之间的比较。
IF 2.5 4区 医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2024-06-20 DOI: 10.1007/s12149-024-01955-z
Ryo Yamakuni, Takenobu Murakami, Naoyuki Ukon, Takeyasu Kakamu, Wataru Toda, Kasumi Hattori, Hirofumi Sekino, Shiro Ishii, Kenji Fukushima, Hiroshi Matsuda, Yoshikazu Ugawa, Noritaka Wakasugi, Mitsunari Abe, Hiroshi Ito

Objective

Centiloid (CL) scales play an important role in semiquantitative analyses of amyloid-β (Aβ) PET. CLs are derived from the standardized uptake value ratio (SUVR), which needs Aβ positron emission tomography (PET) normalization processing. There are two methods to collect the T1-weighted imaging (T1WI) for normalization: (i) anatomical standardization using simultaneously acquired T1WI (PET/MRI), usually adapted to PET images from PET/MRI scanners, and (ii) T1WI from a separate examination (PET + MRI), usually adapted to PET images from PET/CT scanners. This study aimed to elucidate the correlations and differences in CLs between when using the above two T1WI collection methods.

Methods

Among patients who underwent Aβ PET/MRI (using 11C-Pittuberg compound B (11C-PiB) or 18F‐flutemetamol (18F-FMM)) at our institution from 2015 to 2023, we selected 49 patients who also underwent other additional MRI examinations, including T1WI for anatomic standardization within 3 years. Thirty-one of them underwent 11C‐PiB PET/MRI, and 18 participants underwent 18F‐FMM PET/MRI. Twenty-five of them, additional MRI acquisition parameters were identical to simultaneous MRI during PET, and 24 participants were different. After normalization using PET/MRI or PET + MRI method each, SUVR was measured using the Global Alzheimer’s Association Initiative Network cerebral cortical and striatum Volume of Interest templates (VOI) and whole cerebellum VOI. Subsequently, CLs were calculated using the previously established equations for each Aβ PET tracer.

Results

Between PET/MRI and PET + MRI methods, CLs correlated linearly in 11C-PiB PET (y = 1.00x – 0.11, R2 = 0.999), 18F-FMM PET (y = 0.97x – 0.12, 0.997), identical additional MRI acquisition (y = 1.00x + 0.33, 0.999), different acquisition (y = 0.98x – 0.43, 0.997), and entire study group (y = 1.00x – 0.24, 0.999). Wilcoxon signed-rank test revealed no significant differences: 11C-PiB (p = 0.49), 18F-FMM (0.08), and whole PET (0.46). However, significant differences were identified in identical acquisition (p = 0.04) and different acquisition (p = 0.02). Bland–Altman analysis documented only a small bias between PET/MRI and PET + MRI in 11C‐PiB PET, 18F‐FMM PET, identical additional MRI acquisition, different acquisition, and whole PET (– 0.05, 0.67, – 0.30, 0.78, and 0.21, respectively).

Conclusions

Anatomical standardizations using PET/MRI and using PET + MRI can lead to almost equivalent CL. The CL values obtained using PET/MRI or PET + MRI normalization methods are consistent and comparable in clinical studies.

目的:在淀粉样蛋白-β(Aβ)PET 的半定量分析中,Centiloid(CL)标度起着重要作用。CL来自标准化摄取值比值(SUVR),SUVR需要进行Aβ正电子发射断层扫描(PET)归一化处理。收集用于归一化的 T1 加权成像(T1WI)有两种方法:(i) 使用同时获得的 T1WI(PET/MRI)进行解剖标准化,通常适用于 PET/MRI 扫描仪的 PET 图像;(ii) 来自单独检查(PET + MRI)的 T1WI,通常适用于 PET/CT 扫描仪的 PET 图像。本研究旨在阐明使用上述两种T1WI采集方法时CL的相关性和差异:从2015年至2023年在我院接受Aβ PET/MRI(使用11C-Pittuberg化合物B(11C-PiB)或18F-氟替美托(18F-FMM))检查的患者中,我们选取了49名在3年内还接受了其他额外MRI检查(包括T1WI)以进行解剖标准化的患者。其中 31 人接受了 11C-PiB PET/MRI,18 人接受了 18F-FMM PET/MRI。其中 25 人的其他 MRI 采集参数与 PET 期间的同步 MRI 相同,24 人不同。在分别使用 PET/MRI 或 PET + MRI 方法进行归一化后,使用全球阿尔茨海默氏症协会倡议网络大脑皮层和纹状体感兴趣体积模板(VOI)以及整个小脑 VOI 测量 SUVR。随后,使用之前为每种 Aβ PET 示踪剂建立的公式计算 CL:在 PET/MRI 和 PET + MRI 方法之间,CLs 在 11C-PiB PET(y = 1.00x - 0.11,R2 = 0.999)、18F-FMM PET(y = 0.97x - 0.12,0.997)、相同的额外 MRI 采集(y = 1.00x + 0.33,0.999)、不同的采集(y = 0.98x - 0.43,0.997)和整个研究组(y = 1.00x - 0.24,0.999)中呈线性相关。Wilcoxon 符号秩检验显示无显著差异:11C-PiB (p = 0.49)、18F-FMM (0.08) 和整个 PET (0.46)。然而,相同采集(p = 0.04)和不同采集(p = 0.02)之间存在明显差异。Bland-Altman分析表明,在11C-PiB PET、18F-FMM PET、相同的额外MRI采集、不同的采集和整个PET中,PET/MRI和PET + MRI之间只有很小的偏差(分别为- 0.05、0.67、- 0.30、0.78和0.21):结论:使用 PET/MRI 和 PET + MRI 进行解剖标准化可获得几乎相同的 CL 值。在临床研究中,使用 PET/MRI 或 PET + MRI 归一化方法获得的 CL 值具有一致性和可比性。
{"title":"Differential centiloid scale normalization techniques: comparison between hybrid PET/MRI and independently acquired MRI","authors":"Ryo Yamakuni,&nbsp;Takenobu Murakami,&nbsp;Naoyuki Ukon,&nbsp;Takeyasu Kakamu,&nbsp;Wataru Toda,&nbsp;Kasumi Hattori,&nbsp;Hirofumi Sekino,&nbsp;Shiro Ishii,&nbsp;Kenji Fukushima,&nbsp;Hiroshi Matsuda,&nbsp;Yoshikazu Ugawa,&nbsp;Noritaka Wakasugi,&nbsp;Mitsunari Abe,&nbsp;Hiroshi Ito","doi":"10.1007/s12149-024-01955-z","DOIUrl":"10.1007/s12149-024-01955-z","url":null,"abstract":"<div><h3>Objective</h3><p>Centiloid (CL) scales play an important role in semiquantitative analyses of amyloid-β (Aβ) PET. CLs are derived from the standardized uptake value ratio (SUVR), which needs Aβ positron emission tomography (PET) normalization processing. There are two methods to collect the T1-weighted imaging (T1WI) for normalization: (i) anatomical standardization using simultaneously acquired T1WI (PET/MRI), usually adapted to PET images from PET/MRI scanners, and (ii) T1WI from a separate examination (PET + MRI), usually adapted to PET images from PET/CT scanners. This study aimed to elucidate the correlations and differences in CLs between when using the above two T1WI collection methods.</p><h3>Methods</h3><p>Among patients who underwent Aβ PET/MRI (using <sup>11</sup>C-Pittuberg compound B (<sup>11</sup>C-PiB) or <sup>18</sup>F‐flutemetamol (<sup>18</sup>F-FMM)) at our institution from 2015 to 2023, we selected 49 patients who also underwent other additional MRI examinations, including T1WI for anatomic standardization within 3 years. Thirty-one of them underwent <sup>11</sup>C‐PiB PET/MRI, and 18 participants underwent <sup>18</sup>F‐FMM PET/MRI. Twenty-five of them, additional MRI acquisition parameters were identical to simultaneous MRI during PET, and 24 participants were different. After normalization using PET/MRI or PET + MRI method each, SUVR was measured using the Global Alzheimer’s Association Initiative Network cerebral cortical and striatum Volume of Interest templates (VOI) and whole cerebellum VOI. Subsequently, CLs were calculated using the previously established equations for each Aβ PET tracer.</p><h3>Results</h3><p>Between PET/MRI and PET + MRI methods, CLs correlated linearly in <sup>11</sup>C-PiB PET (<i>y</i> = 1.00<i>x</i> – 0.11, <i>R</i><sup>2</sup> = 0.999), <sup>18</sup>F-FMM PET (<i>y</i> = 0.97<i>x</i> – 0.12, 0.997), identical additional MRI acquisition (<i>y</i> = 1.00<i>x</i> + 0.33, 0.999), different acquisition (<i>y</i> = 0.98<i>x</i> – 0.43, 0.997), and entire study group (<i>y</i> = 1.00<i>x</i> – 0.24, 0.999). Wilcoxon signed-rank test revealed no significant differences: <sup>11</sup>C-PiB (<i>p</i> = 0.49), <sup>18</sup>F-FMM (0.08), and whole PET (0.46). However, significant differences were identified in identical acquisition (<i>p</i> = 0.04) and different acquisition (<i>p</i> = 0.02). Bland–Altman analysis documented only a small bias between PET/MRI and PET + MRI in <sup>11</sup>C‐PiB PET, <sup>18</sup>F‐FMM PET, identical additional MRI acquisition, different acquisition, and whole PET (– 0.05, 0.67, – 0.30, 0.78, and 0.21, respectively).</p><h3>Conclusions</h3><p>Anatomical standardizations using PET/MRI and using PET + MRI can lead to almost equivalent CL. The CL values obtained using PET/MRI or PET + MRI normalization methods are consistent and comparable in clinical studies.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"38 10","pages":"835 - 846"},"PeriodicalIF":2.5,"publicationDate":"2024-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141431217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction to: Annals of Nuclear Medicine 更正为核医学年鉴》。
IF 2.5 4区 医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2024-06-19 DOI: 10.1007/s12149-024-01953-1
{"title":"Correction to: Annals of Nuclear Medicine","authors":"","doi":"10.1007/s12149-024-01953-1","DOIUrl":"10.1007/s12149-024-01953-1","url":null,"abstract":"","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"38 7","pages":"586 - 586"},"PeriodicalIF":2.5,"publicationDate":"2024-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141417491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction: Novel indices representing heterogeneous distributions of myocardial perfusion imaging 更正:代表心肌灌注成像异质性分布的新指数。
IF 2.5 4区 医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2024-06-17 DOI: 10.1007/s12149-024-01951-3
Misato Chimura, Tomohito Ohtani, Fusako Sera, Rie Higuchi, Kenji Kajitani, Kenichi Nakajima, Yasushi Sakata
{"title":"Correction: Novel indices representing heterogeneous distributions of myocardial perfusion imaging","authors":"Misato Chimura,&nbsp;Tomohito Ohtani,&nbsp;Fusako Sera,&nbsp;Rie Higuchi,&nbsp;Kenji Kajitani,&nbsp;Kenichi Nakajima,&nbsp;Yasushi Sakata","doi":"10.1007/s12149-024-01951-3","DOIUrl":"10.1007/s12149-024-01951-3","url":null,"abstract":"","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"38 7","pages":"584 - 585"},"PeriodicalIF":2.5,"publicationDate":"2024-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11217040/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141330322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Should new organ involvement be included in Response Evaluation Criteria in PSMA Imaging? 新器官受累是否应纳入 PSMA 成像的反应评估标准?
IF 2.5 4区 医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2024-06-16 DOI: 10.1007/s12149-024-01954-0
İhsan Kaplan, Halil Kömek, Canan Can, Nadiye Akdeniz, Yunus Güzel, Ferat Kepenek, Ayhan Şenol, Serdar İleri, Hüseyin Karaoğlan, İhsan Solmaz, Mehmet Serdar Yıldırım, Veysi Şenses, Fulya Kaya, Cihan Gündoğan

Purpose

The current study is intended to investigate the effect of new organ involvement on overall survival (OS) and modify the Response Evaluation Criteria in PSMA Imaging (RECIP) by including new organ involvement to RECIP 1.0.

Materials and methods

This retrospective study includes 114 patients diagnosed with metastatic castration-resistant prostate cancer (mCRPC) between September 2017 and June 2022 who had received docetaxel treatment and had baseline and post-treatment prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) images. The inclusion criteria were patients with pre- and post-treatment [18F]FDG PET/CT images and whose [18F]FDG PET images were negative. Those whose data were unavailable, who had additional malignancy, or who received abiraterone, enzalutamide, or Lutetium (Lu)-177 treatment were excluded. Age, Gleason score (GS), TPSA (total prostate-specific antigen) levels, surgical history, and OS information were recorded for each patient.

Results

The 114 patients herein had a median age of 72.5 (51–91) years and a median GS of 8 (7–10). New lesions were observed in 59 patients (51.7%) and new organ PSMA uptake was observed in 14 patients (12.2%). In the multivariate Cox regression analysis, volume-based treatment response (vTR)-total lesion PSMA (TLP), RECIP PSMA-VOL, modified RECIP (mRECIP) PSMA-VOL, and mRECIP TLP were independent prognostic factors for mortality (p < 0.001, p = 0.006, p = 0.003, and p = 0.003, respectively). The median OS of patients with new organ involvement and new lesion with PSMA uptake was 9.3 months (95% CI 2.1–16.5 months) and 11.8 months (95% CI 7.4–16.2 months), respectively.

Conclusion

The study concluded that new organ involvement had a shorter OS than new lesion involvement. In the mRECIP that we developed, unlike RECIP, we demonstrated that both PSMA-VOL and TLP value were independent prognostic factors for mortality.

目的:本研究旨在调查新器官受累对总生存期(OS)的影响,并通过将新器官受累纳入RECIP 1.0来修改PSMA影像学反应评估标准(RECIP):这项回顾性研究纳入了2017年9月至2022年6月期间诊断为转移性去势抵抗性前列腺癌(mCRPC)的114例患者,这些患者接受了多西他赛治疗,并具有基线和治疗后前列腺特异性膜抗原(PSMA)正电子发射断层扫描/计算机断层扫描(PET/CT)图像。纳入标准是具有治疗前和治疗后[18F]FDG PET/CT 图像且[18F]FDG PET 图像为阴性的患者。数据不详、患有其他恶性肿瘤或接受过阿比特龙、恩扎鲁胺或镥(Lu)-177 治疗的患者不在纳入之列。记录了每位患者的年龄、格里森评分(GS)、TPSA(总前列腺特异性抗原)水平、手术史和OS信息:114名患者的中位年龄为72.5(51-91)岁,中位GS为8(7-10)分。59名患者(51.7%)出现新病灶,14名患者(12.2%)出现新的器官PSMA摄取。在多变量考克斯回归分析中,基于容积的治疗反应(vTR)-总病灶 PSMA(TLP)、RECIP PSMA-VOL、改良 RECIP(mRECIP)PSMA-VOL 和 mRECIP TLP 是死亡率的独立预后因素(p 结论:该研究得出结论,新器官受累是导致癌症死亡的重要因素:该研究认为,新器官受累的 OS 短于新病灶受累的 OS。在我们开发的 mRECIP 中,与 RECIP 不同的是,我们证明 PSMA-VOL 和 TLP 值都是死亡率的独立预后因素。
{"title":"Should new organ involvement be included in Response Evaluation Criteria in PSMA Imaging?","authors":"İhsan Kaplan,&nbsp;Halil Kömek,&nbsp;Canan Can,&nbsp;Nadiye Akdeniz,&nbsp;Yunus Güzel,&nbsp;Ferat Kepenek,&nbsp;Ayhan Şenol,&nbsp;Serdar İleri,&nbsp;Hüseyin Karaoğlan,&nbsp;İhsan Solmaz,&nbsp;Mehmet Serdar Yıldırım,&nbsp;Veysi Şenses,&nbsp;Fulya Kaya,&nbsp;Cihan Gündoğan","doi":"10.1007/s12149-024-01954-0","DOIUrl":"10.1007/s12149-024-01954-0","url":null,"abstract":"<div><h3>Purpose</h3><p>The current study is intended to investigate the effect of new organ involvement on overall survival (OS) and modify the Response Evaluation Criteria in PSMA Imaging (RECIP) by including new organ involvement to RECIP 1.0.</p><h3>Materials and methods</h3><p>This retrospective study includes 114 patients diagnosed with metastatic castration-resistant prostate cancer (mCRPC) between September 2017 and June 2022 who had received docetaxel treatment and had baseline and post-treatment prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) images. The inclusion criteria were patients with pre- and post-treatment [<sup>18</sup>F]FDG PET/CT images and whose [<sup>18</sup>F]FDG PET images were negative. Those whose data were unavailable, who had additional malignancy, or who received abiraterone, enzalutamide, or Lutetium (Lu)-177 treatment were excluded. Age, Gleason score (GS), TPSA (total prostate-specific antigen) levels, surgical history, and OS information were recorded for each patient.</p><h3>Results</h3><p>The 114 patients herein had a median age of 72.5 (51–91) years and a median GS of 8 (7–10). New lesions were observed in 59 patients (51.7%) and new organ PSMA uptake was observed in 14 patients (12.2%). In the multivariate Cox regression analysis, volume-based treatment response (vTR)-total lesion PSMA (TLP), RECIP PSMA-VOL, modified RECIP (mRECIP) PSMA-VOL, and mRECIP TLP were independent prognostic factors for mortality (<i>p</i> &lt; 0.001, <i>p</i> = 0.006, <i>p</i> = 0.003, and <i>p</i> = 0.003, respectively). The median OS of patients with new organ involvement and new lesion with PSMA uptake was 9.3 months (95% CI 2.1–16.5 months) and 11.8 months (95% CI 7.4–16.2 months), respectively.</p><h3>Conclusion</h3><p>The study concluded that new organ involvement had a shorter OS than new lesion involvement. In the mRECIP that we developed, unlike RECIP, we demonstrated that both PSMA-VOL and TLP value were independent prognostic factors for mortality.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"38 10","pages":"825 - 834"},"PeriodicalIF":2.5,"publicationDate":"2024-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141330245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Inverse correlation between age of onset and myocardial amyloid deposition quantified by 99mTc-PYP scintigraphy in patients with wild-type transthyretin amyloid cardiomyopathy 野生型转甲状腺素淀粉样变性心肌病患者的发病年龄与通过99m锝-PYP闪烁成像量化的心肌淀粉样沉积之间存在反相关性。
IF 2.5 4区 医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2024-06-14 DOI: 10.1007/s12149-024-01943-3
Hiroshi Kanaya, Shinya Shiraishi, Kouji Ogasawara, Koya Iwashita, Fumi Sakamoto, Seiji Takashio, Yoshiki Mikami, Kenichi Tsujita, Toshinori Hirai

Objective

Wild-type transthyretin amyloidosis cardiomyopathy (ATTRwt-CM) is increasingly recognized as a contributing factor to cardiac insufficiency in the elderly population. We aimed to identify the factors affecting age of onset of ATTRwt-CM, encompassing the assessment of amyloid deposition in myocardial tissue through the use of 99mTc-pyrophosphate (PYP) and clinical parameters.

Methods

A retrospective investigation involving a consecutive cohort of 107 cases, each having been diagnosed with ATTRwt-CM confirmed through histopathological and genetic analysis, was performed. All patients underwent PYP scintigraphy, and the heart-to-contralateral (H/CL) ratio was calculated to measure amyloid deposition in the myocardium. Univariate and multivariate analyses were performed to identify independent predictors of the age of onset of ATTRwt-CM, considering the H/CL ratio and various clinical risk factors for heart failure.

Results

Gender (p = 0.03), Creatinine (Cr) (r = 0.32, p < 0.01), hemoglobin (Hb) (r =  − 0.44, p < 0.01), albumin (Alb) (r =  − 0.32, p < 0.01), brain natriuretic peptide (BNP) (r = 0.21, p = 0.03), low-density lipoprotein-cholesterol (LDL-C) (r =  − 0.27, p < 0.01), and H/CL ratio (r =  − 0.44, p < 0.01) were all significantly associated with the onset age. In multiple regression analysis, the independent predictive factors for the onset age of ATTRwt-CM were identified as the H/CL ratio (p < 0.01), Hb (p < 0.01), and Cr (p < 0.01).

Conclusion

The H/CL ratio, Hb, and Cr independently affect age of onset in patients with ATTRwt-CM. The H/CL ratio is inversely correlated with age of onset, and may be the sole factor in the development of heart failure in early onset patients, while it may have a synergistic effect on heart failure with anemia and renal dysfunction in late-onset patients.

目的:野生型转甲状腺素淀粉样变性心肌病(ATTRwt-CM)越来越被认为是导致老年人心功能不全的一个因素。我们旨在确定影响 ATTRwt-CM 发病年龄的因素,包括通过使用 99mTc 焦磷酸(PYP)和临床参数评估心肌组织中的淀粉样沉积:方法:我们进行了一项回顾性调查,涉及 107 例连续性病例,每例病例均通过组织病理学和基因分析确诊为 ATTRwt-CM。所有患者都接受了PYP闪烁扫描,并计算了心脏与心肌两侧(H/CL)的比率,以测量心肌中的淀粉样沉积。考虑到H/CL比值和心衰的各种临床风险因素,进行了单变量和多变量分析,以确定ATTRwt-CM发病年龄的独立预测因素:性别(P = 0.03)、肌酐(Cr)(r = 0.32,PH/CL比值、Hb和Cr对ATTRwt-CM患者的发病年龄有独立影响。H/CL 比值与发病年龄成反比,可能是早发患者发生心衰的唯一因素,而在晚发患者中,H/CL 比值可能与贫血和肾功能障碍对心衰有协同作用。
{"title":"Inverse correlation between age of onset and myocardial amyloid deposition quantified by 99mTc-PYP scintigraphy in patients with wild-type transthyretin amyloid cardiomyopathy","authors":"Hiroshi Kanaya,&nbsp;Shinya Shiraishi,&nbsp;Kouji Ogasawara,&nbsp;Koya Iwashita,&nbsp;Fumi Sakamoto,&nbsp;Seiji Takashio,&nbsp;Yoshiki Mikami,&nbsp;Kenichi Tsujita,&nbsp;Toshinori Hirai","doi":"10.1007/s12149-024-01943-3","DOIUrl":"10.1007/s12149-024-01943-3","url":null,"abstract":"<div><h3>Objective</h3><p>Wild-type transthyretin amyloidosis cardiomyopathy (ATTRwt-CM) is increasingly recognized as a contributing factor to cardiac insufficiency in the elderly population. We aimed to identify the factors affecting age of onset of ATTRwt-CM, encompassing the assessment of amyloid deposition in myocardial tissue through the use of <sup>99m</sup>Tc-pyrophosphate (PYP) and clinical parameters.</p><h3>Methods</h3><p>A retrospective investigation involving a consecutive cohort of 107 cases, each having been diagnosed with ATTRwt-CM confirmed through histopathological and genetic analysis, was performed. All patients underwent PYP scintigraphy, and the heart-to-contralateral (H/CL) ratio was calculated to measure amyloid deposition in the myocardium. Univariate and multivariate analyses were performed to identify independent predictors of the age of onset of ATTRwt-CM, considering the H/CL ratio and various clinical risk factors for heart failure.</p><h3>Results</h3><p>Gender (<i>p = </i>0.03), Creatinine (Cr) (<i>r = </i>0.32, p &lt; 0.01), hemoglobin (Hb) (<i>r = </i> − 0.44, <i>p &lt; </i>0.01), albumin (Alb) (<i>r = </i> − 0.32, <i>p &lt; </i>0.01), brain natriuretic peptide (BNP) (<i>r = </i>0.21, <i>p = </i>0.03), low-density lipoprotein-cholesterol (LDL-C) (<i>r = </i> − 0.27, <i>p &lt; </i>0.01), and H/CL ratio (<i>r = </i> − 0.44, <i>p &lt; </i>0.01) were all significantly associated with the onset age. In multiple regression analysis, the independent predictive factors for the onset age of ATTRwt-CM were identified as the H/CL ratio (<i>p &lt; </i>0.01), Hb (<i>p &lt; </i>0.01), and Cr (<i>p &lt; </i>0.01).</p><h3>Conclusion</h3><p>The H/CL ratio, Hb, and Cr independently affect age of onset in patients with ATTRwt-CM. The H/CL ratio is inversely correlated with age of onset, and may be the sole factor in the development of heart failure in early onset patients, while it may have a synergistic effect on heart failure with anemia and renal dysfunction in late-onset patients.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"38 9","pages":"744 - 753"},"PeriodicalIF":2.5,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141316599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Novel prediction model combining PET/CT metabolic parameters, inflammation markers, and TNM stage: prospects for personalizing prognosis in nasopharyngeal carcinoma 结合 PET/CT 代谢参数、炎症标记物和 TNM 分期的新型预测模型:鼻咽癌个性化预后的前景。
IF 2.5 4区 医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2024-06-14 DOI: 10.1007/s12149-024-01949-x
Huan Liang, Weilin Tan, Jie Wang, Mengdan Li, Hua Pang, Xiaohui Wang, Lu Yang, Xingguo Jing

Purpose

This study aims to develop a novel prediction model and risk stratification system that could accurately predict progression-free survival (PFS) in patients with nasopharyngeal carcinoma (NPC).

Methods

Herein, we included 106 individuals diagnosed with NPC, who underwent 18F-FDG PET/CT scanning before treatment. They were divided into training (n = 76) and validation (n = 30) sets. The prediction model was constructed based on multivariate Cox regression analysis results and its predictive performance was evaluated. Risk factor stratification was performed based on the nomogram scores of each case, and Kaplan–Meier curves were used to evaluate the model’s discriminative ability for high- and low-risk groups.

Results

Multivariate Cox regression analysis showed that N stage, M stage, SUVmax, MTV, HI, and SIRI were independent factors affecting the prognosis of patients with NPC. In the training set, the model considerably outperformed the TNM stage in predicting PFS (AUCs of 0.931 vs. 0.841, 0.892 vs. 0.785, and 0.892 vs. 0.804 at 1–3 years, respectively). The calibration plots showed good agreement between actual observations and model predictions. The DCA curves further justified the effectiveness of the model in clinical practice. Between high- and low-risk group, 3-year PFS rates were significantly different (high- vs. low-risk group: 62.8% vs. 9.8%, p < 0.001). Adjuvant chemotherapy was also effective for prolonging survival in high-risk patients (p = 0.009).

Conclusion

Herein, a novel prediction model was successfully developed and validated to improve the accuracy of prognostic prediction for patients with NPC, with the aim of facilitating personalized treatment.

目的:本研究旨在开发一种新型预测模型和风险分层系统,以准确预测鼻咽癌(NPC)患者的无进展生存期(PFS)。方法:本研究纳入了 106 名确诊为鼻咽癌的患者,他们在治疗前接受了 18F-FDG PET/CT 扫描。他们被分为训练集(76 人)和验证集(30 人)。根据多元 Cox 回归分析结果构建预测模型,并评估其预测性能。根据每个病例的提名图评分对风险因素进行分层,并利用 Kaplan-Meier 曲线评估模型对高风险组和低风险组的区分能力:多变量 Cox 回归分析显示,N 分期、M 分期、SUVmax、MTV、HI 和 SIRI 是影响鼻咽癌患者预后的独立因素。在训练集中,该模型在预测PFS方面大大优于TNM分期(1-3年的AUC分别为0.931 vs. 0.841、0.892 vs. 0.785和0.892 vs. 0.804)。校准图显示,实际观测结果与模型预测结果之间存在良好的一致性。DCA曲线进一步证明了该模型在临床实践中的有效性。高危组和低危组的 3 年生存率有显著差异(高危组 62.8% 对低危组 9.8%):62.8% vs. 9.8%,P 结论:这是一个新的预测模型:本文成功开发并验证了一种新型预测模型,以提高鼻咽癌患者预后预测的准确性,从而促进个性化治疗。
{"title":"Novel prediction model combining PET/CT metabolic parameters, inflammation markers, and TNM stage: prospects for personalizing prognosis in nasopharyngeal carcinoma","authors":"Huan Liang,&nbsp;Weilin Tan,&nbsp;Jie Wang,&nbsp;Mengdan Li,&nbsp;Hua Pang,&nbsp;Xiaohui Wang,&nbsp;Lu Yang,&nbsp;Xingguo Jing","doi":"10.1007/s12149-024-01949-x","DOIUrl":"10.1007/s12149-024-01949-x","url":null,"abstract":"<div><h3>Purpose</h3><p>This study aims to develop a novel prediction model and risk stratification system that could accurately predict progression-free survival (PFS) in patients with nasopharyngeal carcinoma (NPC).</p><h3>Methods</h3><p>Herein, we included 106 individuals diagnosed with NPC, who underwent <sup>18</sup>F-FDG PET/CT scanning before treatment. They were divided into training (<i>n</i> = 76) and validation (<i>n</i> = 30) sets. The prediction model was constructed based on multivariate Cox regression analysis results and its predictive performance was evaluated. Risk factor stratification was performed based on the nomogram scores of each case, and Kaplan–Meier curves were used to evaluate the model’s discriminative ability for high- and low-risk groups.</p><h3>Results</h3><p>Multivariate Cox regression analysis showed that N stage, M stage, SUV<sub>max</sub>, MTV, HI, and SIRI were independent factors affecting the prognosis of patients with NPC. In the training set, the model considerably outperformed the TNM stage in predicting PFS (AUCs of 0.931 vs. 0.841, 0.892 vs. 0.785, and 0.892 vs. 0.804 at 1–3 years, respectively). The calibration plots showed good agreement between actual observations and model predictions. The DCA curves further justified the effectiveness of the model in clinical practice. Between high- and low-risk group, 3-year PFS rates were significantly different (high- vs. low-risk group: 62.8% vs. 9.8%, <i>p</i> &lt; 0.001). Adjuvant chemotherapy was also effective for prolonging survival in high-risk patients (<i>p</i> = 0.009).</p><h3>Conclusion</h3><p>Herein, a novel prediction model was successfully developed and validated to improve the accuracy of prognostic prediction for patients with NPC, with the aim of facilitating personalized treatment.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"38 10","pages":"802 - 813"},"PeriodicalIF":2.5,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141316601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Annals of Nuclear Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1